C ardiovascular diseases, such as vascular calcification, are the major cause of morbidity and mortality in patients with chronic kidney disease (CKD). 1, 2 CKD is represented by states of low-grade chronic inflammation characterized by increased levels of inflammatory markers such as tumor necrosis factor-a (TNFa). [3] [4] [5] Several clinical studies show that CKD patients have significantly higher serum TNFa levels, [6] [7] [8] implying that TNFa may play an important role in the pathogenesis of vascular calcification in CKD. TNFa is a pleiotropic cytokine produced by many different types of cells in the body. Previous studies have shown that TNFa signaling participates in vascular calcification. [9] [10] [11] Tintut and Demer first reported that TNFa induced mineralization and osteogenic differentiation of bovine calcifying vascular cells through a phosphate kinase A (PKA)-dependent mechanism. 10 Later, Towler's group reported that (1) low-density lipoprotein receptor (LDLR)-deficient (
) diabetic mice had increased serum TNFa levels, resulting in vascular calcification, and (2) treatment of LDLR À/À diabetic mice with infliximab, a TNFa monoclonal antibody, reduced the extent of vascular calcification. 11 However, the precise molecular mechanism by which TNFa promotes CKD-dependent vascular calcification remains unclear. The endoplasmic reticulum (ER) is a major signal transducing organelle that senses and responds to changes in homeostasis. ER stress is caused by disturbances in the structure and function of the ER, accumulated by misfolded proteins and altered calcium homeostasis. [12] [13] [14] In response to ER stress, the unfolded protein response (UPR) is initiated by the activation of 3 molecules: PKR-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6). PERK activation leads to phosphorylation of the a subunit of eukaryotic initiation factor 2 (eIF2a), which inhibits protein synthesis. [12] [13] [14] In contrast to most proteins, activating transcription factor 4 (ATF4) is not affected by the translational attenuation of eIF2a phosphorylation. Phosphorylation leads to the induction of C/EBP-homologous protein (CHOP), which promotes ER stress-induced apoptosis.
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ATF4 is a pivotal transcription factor that mediates not only ER stress but also osteoblastic differentiation-related genes such as osteocalcin and osterix. 16, 17 ATF4 is regulated through posttranslational phosphorylation by ribosomal S6 kinase 2 (RSK2) and PKA. 17, 18 To increase the transcriptional activity of ATF4, RSK2 and PKA phosphorylate ATF4 at Ser251 and Ser254, respectively. Recent reports from our group and others suggest that the ER stress caused by saturated fatty acids and BMP-2 induces ER stress, leading to the development of vascular calcification. 19, 20 We previously reported that stearate treatment leads to ATF4 activation through ER stress, resulting in mineralization and osteogenic differentiation. 19 We therefore hypothesize that TNFa also induces vascular calcification by activating the PERK-eIF1a-ATF4--CHOP branch of the ER stress signaling pathway.
In this study, we evaluate the following 5 points: whether (1) TNFa induces ER stress in VSMCs, (2) TNFa induces the phosphorylation of ATF4 by PKA and RSK2, resulting in the induction of mineralization and osteoblast differentiation of VSMCs, (3) the PERK-eIF2a-ATF4-CHOP branch contributes to vascular calcification induced by TNFa, (4) CKD induces aortic TNFa, ATF4, and CHOP expression, and (5) inhibition of TNFa attenuates CKD-dependent vascular calcification in ApoE À/À mice with 5/6 nephrectomies by reducing aortic PERKeIF2a-ATF4-CHOP signaling of the ER stress response.
Methods
Cell Culture Studies MOVAS-1 cells were kindly provided by Dr Mansoor Husain at the University of Toronto. Calcifying vascular cells were kindly provided by Drs Yin Tintut and Linda Demer at the University of California, Los Angeles. These cells were cultured in DMEM containing phosphate 1 to 3 mmol/L, 10% FBS, and TNFa 1 to 10 ng/mL. 10, 21, 22 The medium was changed every 2 to 3 days. All cell culture experiments were performed independently at least 2 times.
Animal Studies
Eight-week-old male ApoE À/À mice (C57Bl6/J background)
were purchased from the Jackson Laboratory and subjected to either 5/6 nephrectomy or sham operation. These operations were performed as we previously described. 23 Animals were fed a high-fat/high-cholesterol diet (TD10364; Harlan Teklad) after the operations. Treatment groups consisted of 6 to 17 animals each. Animals were given intraperitoneal injections of the TNFa-neutralizing antibody infliximab (Janssen, 10 mg/kg) 3 times weekly for 10 weeks. A dose of sodium 4-phenylbutyric acid (4-PBA, 250 mg/kg) or tauroursodeoxycholic acid (TUDCA, 250 mg/kg) was injected intraperitoneally once daily for 8 weeks. Animal experiments were approved by the Institutional Animal Care and Research Advisory Committee of the University of Colorado at Denver.
Histological Analysis
Calcified lesions of the aortic valve were analyzed as we previously described. 23, 24 The upper portions of the heart and proximal aorta were obtained, embedded in OCT compound, and stored at À80°C. Ten-micrometer sections were analyzed for a distance of 800 lm. Sections were stained with von Kossa. The calcified areas on 25 sections were determined in a blinded fashion by the use of light microscopy. For each section, the mean value of lesion area of aortic wall per section was calculated.
Calcium Content in Cultured Cells
Calcium deposition in the plates was quantified as previously described. 19, 25 Cells were decalcified using an HCl 0.6 mol/L solution. After collection of the supernatant, the cells were washed with PBS and solubilized with an NaOH 0.1 N/SDS 0.1% solution for protein quantification. Calcium content was quantified calorimetrically using the o-cresolphthalein method. Protein content was measured using a BCA protein assay kit.
RNA Analysis
Total RNA was isolated using TRI Reagent (Molecular Research Center Inc) in conjunction with an RNeasy kit (Qiagen). Real-time quantitative PCR assays were performed using an Applied Biosystems StepOne qPCR instrument as we previously described. 19 Using the Ct (cycle threshold) method, quantification of gene expression was calculated as the mRNA level normalized to a ribosomal housekeeping gene (18S or 36B4). Primer sequences are available on request. The spliced form of X-box binding protein-1 (XBP-1) was analyzed by RT-PCR coupled with PstI digestion, as described previously. 19, 26 CHOP cDNA. Colonies were selected by treatment with puromycin 5 lg/mL for 7 days. A single colony was isolated from MOVAS-1 cells infected with each lentivirus. MOVAS-1 cells treated with CHOP shRNA (V2LMM_16424) which most strongly reduced CHOP expression, were used as CHOPknockdown VSMCs.
Adenoviral Transduction for MOVAS-1 Cells
MOVAS-1 cells were infected with recombinant adenoviruses at a multiplicity of infection (MOI) of 40. An adenovirus expressing wild-type ATF4 and an ATF4 mutant with Ser251Ala and Ser254Ala was generated using the ViraPower Adenovirus Expression System (Invitrogen). MOVAS-1 cells were infected with the adenovirus in DMEM with 10% FBS. After 6 hours, the infected cells were treated with fresh media for 7 days. 
Inorganic Phosphate Uptake Measurement

Western Blotting
Cell and tissue lysates were prepared using RIPA buffer (Cell Signaling). The samples were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and immunoblotted with the following antibodies: ATF4 (Santa Cruz Biotechnology), CHOP (Santa Cruz Biotechnology), GAPDH (Santa Cruz Biotechnology), p-CREB (Cell Signaling), p-ERK (Cell Signaling), p-RSK2 (Cell Signaling), PERK (Cell Signaling), p-PERK (Cell Signaling), p-eIF2a (Cell Signaling), and phospho-serine (Millipore). Nuclear extracts were isolated using a nuclear extract kit (Active Motif) as previously described. 23 Samples were visualized using horseradish peroxidase coupled to an antimouse secondary antibody, with enhancement from an ECL detection kit.
Statistical Analysis
Data were collected from >2 independent experiments and were reported as the meanAESE. Statistical analysis for 10 In the mouse VSMC line MOVAS-1, we found that TNFa treatment significantly increased calcium content and alkaline phosphatase (ALP) activity, consistent with previous studies ( Figure 1A and 1B). 10 Recently, we reported that stearate induces ATF4 activation and contributes to vascular calcification. 19 To determine whether TNFa likewise induces and activates ATF4, the expression and phosphorylation of ATF were analyzed by immunoblotting. Both p-ATF4 and total ATF4 protein expressions were increased after 1 hour of the treatment with TNFa 10 ng/mL ( Figure 1C ). TNFa treatment also increased the levels of phosphorylated RSK2 (p-RSK2) and p-CREB, which are protein kinases that phosphorylate ATF4. Next, we also examined whether this TNFa induction of ATF4 expression occurs through the PERK-eIF2a signaling branch of the UPR. TNFa treatment transiently induced phosphorylation of PERK (p-PERK) and eIF2a (p-eIF2a) protein expression with maximum induction at 30 minutes ( Figure 1C ). The expression of CHOP mRNA increased in MOVAS-1 cells treated with TNFa at 24 to 48 hours (data not shown). The effects of TNFa on CHOP expression, ATF4 expression, and ATF4 phosphorylation were dose dependent ( Figure 1D ). Nuclear p-ATF4 and total ATF4 protein levels also increased in a dose-dependent manner in response to TNFa treatment ( Figure 1E ). TNFa treatment caused a 3.7-fold increase in the mRNA levels of the spliced form of XBP-1 (sXBP-1), another common marker of ER stress ( Figure 1F ). We also confirmed that TNFa induced ER stress in bovine calcifying vascular cells ( Figure S1 ) similar to MOVAS-1 cells. These data suggest that TNFa activates ATF4 though the ER stress response.
Since TNFa has been shown to induce vascular calcification through a PKA-dependent pathway and ATF4 has a PKA-dependent phosphorylation site, 10, 18 we tested whether PKA activation increases phosphorylated ATF4 (p-ATF4). VSMCs were treated with 10 lmol/L of PKA activator forskolin (Fsk). In addition to inducing mineralization and ALP activity, Fsk treatment increased p-ATF4 protein levels without affecting total ATF4 protein levels (data not shown). Phosphorylated CREB (p-CREB) protein levels increased in response to Fsk treatment, as expected. In our time-course experiments, the phosphorylation of ATF4 quickly and transiently increased with Fsk treatment (data not shown). Levels of p-ATF4 were maximally increased by 2.2-fold after 30 minutes of treatment.
To define which kinases activate ATF4 and mediate TNFa regulation of vascular calcification, VSMCs were pretreated with several protein kinase inhibitors (PKA inhibitor H89, MEK inhibitor U0129, RSK inhibitor SL0101-01, p38MAP kinase inhibitor SB203580, and JNK inhibitor SP600125). Consistent with previous reports, 10 whereas U0129 treatment reduced both p-ERK and p-RSK2 levels ( Figure 2B ).
Knockdown of the PERK-eIF2a-ATF4-CHOP Pathway Blocks Mineralization and Osteoblastic Differentiation Induced by TNFa in VSMCs
To confirm whether TNFa induces vascular calcification through the PERK-eIF2a-ATF4 pathway of UPR, we first treated PERK knockdown MOVAS-1 cells with TNFa. 21 PERK knockdown notably diminished mineralization, ALP activity, and downstream ER stress-related proteins (p-ATF4, total ATF4, and CHOP) induced by TNFa. As expected, PERK knockdown reduced protein levels of PERK and its downstream target, p-eIF2a. TNFa-induced sXBP-1 expression was not affected, suggesting the IRE1a-sXBP-1 pathway of the ER stress response ( Figure 3 ) was intact in the PERK knockdown cells.
ATF4 knockdown significantly attenuated TNFa-induced mineralization and ALP activity ( Figure 4A and 4B), similar to stearate-induced vascular calcification. ATF4 knockdown decreased p-ATF4 and total ATF4 protein expression induced by TNFa treatment, resulting in the reduction of TNFa-induced CHOP expression ( Figure 4C ). As expected, the induction of p-eIF2a levels and sXBP-1 levels by TNFa was not altered by ATF4 knockdown ( Figure 4D ). To confirm whether the phosphorylation of ATF4 by PKA and RSK2 is an important event in the mineralization of VSMCs, wild-type ATF4 and the ATF4 double mutant (Ser251Ala and Ser254Ala) were overexpressed in MOVAS-1 cells ( Figure 4E ). Overexpression of wild-type ATF4 stimulated mineralization of VSMCs, whereas double mutations of both ATF4 phosphorylation sites significantly reduced the procalcific effect of ATF4 ( Figure 4F ). These data suggest that serine phosphorylations by PKA and RSK2 are important for the ATF4 activity. Consistent with the immunoblot analysis, qPCR analysis showed that ATF4 knockdown alleviated the expression of TNFa-induced ER stress markers including CHOP, ATF3, asparagine synthetase (ASNS), growth arrest and DNA damageinducible 34 (GADD34), and glucose-regulated protein 78 (GRP78). In addition, ATF4 knockdown rescued the expression of several osteogenic markers including sodium-dependent phosphate transporter 1 (PiT1), osteocalcin (OCN), osteoprotegerin (OPG), Osterix, Runx2, and ALP (Table S1 ). Similarly, PERK knockdown reduced TNFa-induced ER stress markers and osteogenic markers (Table S1) .
Because CHOP is a major mediator of downstream signaling of ATF4, we next examined whether CHOP knockdown affects TNFa-induced vascular calcification in MOVAS-1 cells. Similar to ATF4 knockdown and PERK knockdown, CHOP knockdown diminished TNFa-induced mineralization and ALP activity ( Figure 5A , 5B and 5C). CHOP knockdown blocked CHOP protein levels elevated by TNFa but had no effect on the upstream components such as p-ATF4, total ATF4, and p-eIF2a increased by TNFa ( Figure 5D ). CHOP knockdown decreased mRNA expression of CHOP, GADD34, and osteogenic markers (PiT1, OCN, OPG, Osterix, Runx2, and ALP) induced by TNFa. However, ATF4, ATF3, GRP78, and ASNS mRNA levels did not change (Table S1 ). TNFa-induced sXBP-1 expression also did not change in CHOP knockdown MOVAS-1 cells ( Figure 5E ). Because CHOP is a downstream target of the PERK-eIF2a-ATF4 axis, the expression of upstream components, including p-eIF2a and ATF4, was not affected ( Figure 5C ).
Finally, we determined whether CHOP overexpression induces vascular calcification. Calcium content increased by 3.7-fold in MOVAS-1 cells overexpressing CHOP compared with control MOVAS-1 cells in both the absence and presence of TNFa ( Figure 5G ). To determine the mechanism by which CHOP induces vascular calcification, we analyzed phosphate uptake and PiT-1 expression in MOVAS-1 cells overexpressing CHOP. CHOP overexpression induced PiT-1 expression, resulting in a significant increase in phosphate uptake of MOVAS-1 cells ( Figure 5I and 5H).
ATF4 Expression and Phosphorylation Increased in Murine Models of Atherosclerotic Calcification
To determine whether the PERK-eIF2a-ATF4-CHOP signaling axis contributes to CKD-dependent vascular calcification in vivo, we analyzed aortic protein expression of ATF4 and CHOP in 5/6 nephrectomized (nx) ApoE À/À mice. 23, 29 Nephrectomy increased serum creatinine, urea nitrogen, phosphorus, and cholesterol levels in ApoE sham-operated ApoE À/À mice ( Figure 6D , 6E and 6F).
Aortic CHOP protein levels were also 2.4-fold higher in 5/6 nx ApoE À/À mice ( Figure 6D and 6G).
Inhibition of TNFa reduces PERK-ATF4-CHOP Signaling, Resulting in a Significant Reduction of Vascular Calcification in ApoE À/À Mice
To confirm whether TNFa-induced PERK-eIF2a-ATF4-CHOP signaling contributes to CKD-dependent vascular calcification, we treated 5/6 nx ApoE À/À mice with the TNFa inhibitor infliximab for 8 weeks. Infliximab treatment increased the survival rate of 5/6 nx ApoE À/À mice compared with vehicle treatment ( Figure 7A ). Levels of serum urea nitrogen, cholesterol, and phosphorus increased by CKD did not change by infliximab treatment (Table S2) . Nephrectomy induced aortic calcified lesions by 4.1-fold, which were completely attenuated by infliximab treatment ( Figure 7B and 7C).
To determine whether TNFa inhibition reduces aortic PERK-eIF2a-ATF4-CHOP signaling of the ER stress induced by CKD, we performed qPCR, Western blot, and immunohistochemistry analyses. Infliximab treatment completely reduced CKD-induced ATF4 and CHOP mRNA expression as well as the mRNA expression of their targets, ATF3 and GADD34 ( Figure 7D ). Western blot analysis confirmed that infliximab treatment reduced PERK-ATF4-CHOP signaling induced by CKD ( Figure 7E ). The mRNA levels of 2 osteogenic markers, ALP and osteopontin, were also reduced in the aortas of 5/6 nx ApoE À/À mice treated with infliximab ( Figure 7D ). Consistently, immunohistochemical analysis showed that infliximab treatment reduced aortic CHOP protein expression induced by CKD ( Figure 7F and 7G).
Chemical Chaperones Ameliorate CKD-Dependent Vascular Calcification and ER Stress
To obtain direct evidence that ER stress plays a causative role in CKD-dependent vascular calcification, we treated 5/6 nx ApoE À/À mice with 2 chemical chaperones: 4-PBA and TUDCA. These chemical chaperones are known to attenuate ER stress. Levels of serum urea nitrogen, cholesterol, and phosphorus increased by CKD did not change from 4-PBA treatment (Table S3) . TUDCA treatment reduced serum triglyceride and cholesterol levels but not other parameters. Both 4-PBA and TUDCA treatments reduced mRNA expressions of ER stress markers such as ATF4 and CHOP, osteogenic markers such as ALP, Pit-1, and OCN, and inflammatory makers such as TNFa ( Figure 8A ). In addition, 4-PBA and TUDCA significantly attenuated CKD-induced vascular calcification ( Figure 8B and 8C). 
Discussion
The mechanisms underlying the molecular pathogenesis of vascular calcification in CKD are extremely complex and are influenced by the interaction of severe inflammatory factors, lipids, minerals, and oxidative stress. TNFa, a chief inflammatory cytokine, has been shown to play a major causative role in vascular calcification in advanced atherosclerotic lesions. 11 In addition to inflammation, ER stress may contribute to vascular calcification, as suggested by recent evidence from our group and others. 19, 20, 30 In the present study, we found an important link between TNFa signaling and one of the ER stress signaling pathways, the PERK-eIF2a-ATF4-CHOP axis, in the regulation of CKD-dependent vascular calcification.
The first important conclusion of this study is that the PERK-eIF2a-ATF4-CHOP axis of the ER stress response contributes to TNFa-induced mineralization and osteogenic differentiation in VSMCs. TNFa dose-dependently induced the PERK-eIF2a-ATF4-CHOP pathway in VSMCs, correlated with mineralization of VSMCs. In addition, PERK-, ATF4-, and CHOP-shRNA knockdown inhibited mineralization and osteogenic differentiation induced by TNFa, similar to stearate-induced vascular calcification. Spliced IRE-1 and XBP-1 expressions were intact in these knockdown cells in response to TNFa treatment, suggesting that the IRE-1a-XBP-1 axis of the ER stress response is unlikely to contribute to TNFa-induced vascular calcification.
In addition to the ER stress response, the transcriptional activity of ATF4 is regulated through phosphorylation by PKA and RSK2. [16] [17] [18] In addition to increased expression of ATF4 through ER stress, TNFa simultaneously induced the phosphorylation of ATF4 and the activation of the PKA and MEK-ERK-RSK2 pathways. Phosphorylation of ATF4 by PKA and RSK2 is a critical event in osteoblastic and osteoclastic differentiation for skeletal formation. [16] [17] [18] 31 PKA inhibitor (H89) and RSK inhibitor (SL0101-01) reduced levels of mineralization and p-ATF4 increased by TNFa. Combined treatment with PKA and PSK2 inhibitors further reduced mineralization of VSMCs. ATF4 with double mutations in PKA and RSK2 sites had lower activity on the mineralization of VSMCs than wild-type ATF4. Based on our present study and the prior study of the Tintut and Demer group, 10 we concluded that TNFa promotes vascular calcification by activating ATF4 via 3 pathways: (1) the PERK-eIF2a axis of the ER stress response, (2) the PKA phosphorylation pathway, and (3) the MEK-ERK-RSK2 phosphorylation pathway. While ATF4 is an essential component of osteogenic differentiation, CHOP may be the more crucial regulator of TNFa-induced vascular calcification based on the following evidence: (1) TNFa-induced vascular calcification was inhibited in CHOP-knockdown VSMCs, which have normal ATF4 expression, and (2) CHOP overexpression induced vascular mineralization. However, we cannot rule out the possibility that ATF4 forms a heterodimer with CHOP 32 to promote vascular calcification. It will be important to determine whether ATF4 and CHOP form a heterodimer regulating vascular calcification. The precise mechanism by which the PERK-eIF2a-ATF4-CHOP signaling pathway augments TNFainduced vascular calcification remains unclear, but the mechanism is likely related to increased phosphate uptake. Our results suggest that increased phosphate uptake of VSMCs by the induction of Pit-1 by CHOP contributes to the mechanism. Pit-1 is a major type III sodium-dependent phosphate transporter and has been proposed to be a crucial regulator in vascular calcification. 33 We found that Pit-1 is a major target of the PERK-eIF2a-ATF4-CHOP signaling pathway (Table S1 ). In addition, CHOP significantly increased Pi uptake by increasing Pit-1 expression ( Figure 5H and 5I) . Another important observation of this study is that the activation of the PERK-eIF2a-ATF4-CHOP axis of the ER stress response contributes to CKD-dependent vascular calcification in vivo. Vascular calcification is a common feature of CKD and is associated with increased morbidity and mortality of subjects with CKD. Subjects with CKD have a higher serum TNFa level than subjects with normal kidney function. [6] [7] [8] In this study, we found that CKD induced by 5/ 6 nephrectomies led to increased aortic expression of TNFa in ApoE À/À mice, along with increased aortic vascular calcification. Aortic ATF4 and CHOP expressions were significantly higher in 5/6 nx ApoE À/À mice compared with sham-operated controls. The TNFa neutralizing monoclonal antibody infliximab reduced aortic PERK-eIF2a-ATF4-CHOP signaling induced by CKD. This resulted in a complete inhibition of CKD-dependent vascular calcification without affecting serum cholesterol and phosphorus levels (Table  S2 ). In addition, attenuation of ER stress by 2 chemical chaperones, 4-PBA and TUDCA, resulted in a significant reduction of CKD-dependent vascular calcification. These results suggest that TNFa plays a causative role in CKD-dependent vascular calcification through the activation of PERK-eIF2a-ATF4-CHOP signaling (Figure 8 ).
In addition to TNFa-induced vascular calcification, we previously reported that the PERK-eIF2a-ATF4 axis contributed to stearate-induced vascular calcification. 19, 25 Other positive regulators such as high phosphate levels, oxidized lipids (oxysterols and oxidized phospholipids), bone morphogenetic protein-2, and basic fibroblast growth factor strongly induce the PERK-eIF2a-ATF4-CHOP axis of ER stress in VSMCs. Furthermore, we found that the PERK-eIF2a-ATF4-CHOP axis was induced in other murine models of vascular calcification such as 5/6 nx DBA/2J mice and Klotho knockout mice (data not shown). In summary, the results presented here show that TNFa activates the PERK-eIF2a-ATF4-CHOP axis of the ER stress signaling. In addition, TNFa activates 2 protein kinases, PKA and RSK2. As shown schematically in Figure 9 , TNFa activation of protein kinases RSK2 and PKA lead to the phosphorylation of ATF4, which is increased though ER stress signaling. Activation of ATF4 induces the expression of CHOP and leads to increased inorganic phosphate uptake by inducing type III sodium-dependent phosphate transporter, Pit-1. Activation of the PERK-eIF2a-ATF4-CHOP axis of the ER stress therefore appears to be a major event in the pathogenesis of vascular calcification and is emerging as a promising target for treatment of CKD-dependent vascular calcification.
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